Arcellx, Inc. (Nasdaq: ACLX) said that its CART-ddBCMA investigational new drug (IND) for the treatment of relapsed or refractory multiple myeloma (rrMM) has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). 

The clinical hold was initiated following a patient death, and the company is working with the FDA to modify the protocol to provide additional treatment options. While the clinical hold is in effect, Arcellx has received clearance to continue dosing patients who have undergone lymphodepletion.

$ACLX closed at $35.80, down $1.24 (-3.35%) on Friday

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) presented data from its Phase 2 trial, showing sustained and progressive weight loss in patients with hypothalamic obesity treated with setmelanotide over a six-month period. 

The trial included 18 patients, and 13 of them completed the six-month treatment. The data highlights a mean reduction in body mass index (BMI) of 21.0% at month 6 from baseline, with 76.9% of patients achieving a 10% or greater BMI reduction. Significant decreases in fat mass and lean muscle mass were also observed. 

The data demonstrated improvements in the severity of obesity and weight classification. Setmelanotide was well tolerated, with no new safety concerns reported.

On Friday, $RYTM closed at $18.42, reflecting an increase of $0.14 (+0.77%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)